The clinical significance of the lymph node ratio as a recurrence indicator in ampullary cancer after curative pancreaticoduodenectomy.


Journal

Langenbeck's archives of surgery
ISSN: 1435-2451
Titre abrégé: Langenbecks Arch Surg
Pays: Germany
ID NLM: 9808285

Informations de publication

Date de publication:
08 Oct 2024
Historique:
received: 10 02 2024
accepted: 16 09 2024
medline: 8 10 2024
pubmed: 8 10 2024
entrez: 8 10 2024
Statut: epublish

Résumé

The clinical significance of the lymph node ratio (LNR), the number of metastatic lymph nodes per dissected lymph node, has not been sufficiently clarified in ampullary cancer. Among patients diagnosed histopathologically with ampullary cancer between 1980 and 2018, the study included 106 who underwent pathological radical resection by pancreaticoduodenectomy. The relationships between the LNR and metastatic lymph node sites and prognosis were examined. Multivariate analysis revealed that sex and lymph node metastasis were independent prognostic factors. In the 46 patients (43%) with metastatic lymph nodes, the LNR in the recurrence group was significantly higher than that in the non-recurrence group (0.15 ± 0.11 vs. 0.089 ± 0.071, p = 0.025). The receiver operating characteristic curve demonstrated that the LNR cut-off value, 0.07 (area under the curve = 0.70, sensitivity 81%, specificity 56%), was a significant indicator for recurrence (22% vs. 61%, p = 0.016) and prognosis (5-year survival: 48% vs. 83%, p = 0.028). Among the metastatic lymph node sites in the 46 positive cases, lymph node metastases developed from the peripancreatic head region (80%, 37/46) to the superior mesenteric artery (33%, 15/46) and para-aortic (11%, 5/46) regions. Lymph node metastasis is an independent prognostic factor, and the LNR is a significant indicator for recurrence and prognosis in patients with ampullary cancer.

Sections du résumé

BACKGROUND BACKGROUND
The clinical significance of the lymph node ratio (LNR), the number of metastatic lymph nodes per dissected lymph node, has not been sufficiently clarified in ampullary cancer.
METHODS METHODS
Among patients diagnosed histopathologically with ampullary cancer between 1980 and 2018, the study included 106 who underwent pathological radical resection by pancreaticoduodenectomy. The relationships between the LNR and metastatic lymph node sites and prognosis were examined.
RESULTS RESULTS
Multivariate analysis revealed that sex and lymph node metastasis were independent prognostic factors. In the 46 patients (43%) with metastatic lymph nodes, the LNR in the recurrence group was significantly higher than that in the non-recurrence group (0.15 ± 0.11 vs. 0.089 ± 0.071, p = 0.025). The receiver operating characteristic curve demonstrated that the LNR cut-off value, 0.07 (area under the curve = 0.70, sensitivity 81%, specificity 56%), was a significant indicator for recurrence (22% vs. 61%, p = 0.016) and prognosis (5-year survival: 48% vs. 83%, p = 0.028). Among the metastatic lymph node sites in the 46 positive cases, lymph node metastases developed from the peripancreatic head region (80%, 37/46) to the superior mesenteric artery (33%, 15/46) and para-aortic (11%, 5/46) regions.
CONCLUSION CONCLUSIONS
Lymph node metastasis is an independent prognostic factor, and the LNR is a significant indicator for recurrence and prognosis in patients with ampullary cancer.

Identifiants

pubmed: 39377937
doi: 10.1007/s00423-024-03481-y
pii: 10.1007/s00423-024-03481-y
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

302

Informations de copyright

© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Références

Rizzo A, Dadduzio V, Lombardi L, Ricci AD, Gadaleta-Caldarola G (2021) Ampullary carcinoma: an overview of a rare entity and discussion of current and future therapeutic challenges. Curr Oncol 28(5):3393–3402
doi: 10.3390/curroncol28050293 pubmed: 34590592 pmcid: 8482111
Hester CA, Dogeas E, Augustine MM et al (2019) Incidence and comparative outcomes of periampullary cancer: a population-based analysis demonstrating improved outcomes and increased use of adjuvant therapy from 2004 to 2012. J Surg Oncol 119(3):303–317
doi: 10.1002/jso.25336 pubmed: 30561818
Zimmermann C, Wolk S, Aust DE et al (2019) The pathohistological subtype strongly predicts survival in patients with ampullary carcinoma. Sci Rep 9(1):12676
doi: 10.1038/s41598-019-49179-w pubmed: 31481741 pmcid: 6722235
Imamura T, Yamamoto Y, Sugiura T et al (2019) The prognostic relevance of the new, 8th ed. Of the Union for International Cancer Control classification of TNM staging for ampulla of Vater carcinoma. Ann Surg Oncol 26:1639–1648
doi: 10.1245/s10434-019-07238-6 pubmed: 30790111
Howe JR, Klimstra DS, Moccia RD, Conlon KC, Brennan MF (1998) Factors predictive of survival in ampullary carcinoma. Ann Surg 228(1):87–94
doi: 10.1097/00000658-199807000-00013 pubmed: 9671071 pmcid: 1191432
Hatzaras I, George N, Muscarella P, Melvin WS, Ellison EC, Bloomston M (2010) Predictors of survival in periampullary cancers following pancreaticoduodenectomy. Ann Surg Oncol 17(4):991–997
doi: 10.1245/s10434-009-0883-9 pubmed: 20108122 pmcid: 2861840
Ebata T, Hirano S, Konishi M et al (2018) Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. Br J Surg 105(3):192–202
doi: 10.1002/bjs.10776 pubmed: 29405274
Edeline J, Benabdelghani M, Bertaut A et al (2019) Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study. J Clin Oncol 37(8):658–667
doi: 10.1200/JCO.18.00050 pubmed: 30707660
Primrose JN, Fox RP, Palmer DH et al (2019) Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol 20(5):663–673
doi: 10.1016/S1470-2045(18)30915-X pubmed: 30922733
Nakachi K, Ikeda M, Konishi M et al (2023) Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet 401(10372):195–203
doi: 10.1016/S0140-6736(22)02038-4 pubmed: 36681415
Bhamidipati CM, Stukenborg GJ, Thomas CJ, Lau CL, Kozower BD, Jones DR (2012) Pathologic lymph node ratio is a predictor of survival in esophageal cancer. Ann Thorac Surg 94(5):1643–1651
doi: 10.1016/j.athoracsur.2012.03.078 pubmed: 22621876
Marchet A, Mocellin S, Ambrosi A et al (2008) The prognostic value of N-ratio in patients with gastric cancer: validation in a large, multicenter series. Eur J Surg Oncol 34(2):159–165
doi: 10.1016/j.ejso.2007.04.018 pubmed: 17566691
Pawlik TM, Gleisner AL, Cameron JL et al (2007) Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer. Surgery 141(5):610–618
doi: 10.1016/j.surg.2006.12.013 pubmed: 17462460
Peschaud F, Benoist S, Julié C et al (2008) The ratio of metastatic to examined lymph nodes is a powerful independent prognostic factor in rectal cancer. Ann Surg 248(6):1067–1073
doi: 10.1097/SLA.0b013e31818842ec pubmed: 19092352
Falconi M, Crippa S, Domínguez I et al (2008) Prognostic relevance of lymph node ratio and number of resected nodes after curative resection of ampulla of Vater carcinoma. Ann Surg Oncol 15(11):3178–3186
doi: 10.1245/s10434-008-0099-4 pubmed: 18712568
Pomianowska E, Westgaard A, Mathisen Ø, Clausen OP, Gladhaug IP (2013) Prognostic relevance of number and ratio of metastatic lymph nodes in resected pancreatic, ampullary, and distal bile duct carcinomas. Ann Surg Oncol 20(1):233–241
doi: 10.1245/s10434-012-2592-z pubmed: 22893118
Noda T, Ohigashi H, Ishikawa O et al (2007) Liver perfusion chemotherapy for selected patients at a high-risk of liver metastasis after resection of duodenal and ampullary cancers. Ann Surg 246(5):799–805
doi: 10.1097/SLA.0b013e318158fc7f pubmed: 17968172
Kayahara M, Ohta T (2010) Gross appearance of the ampullary tumor predicts lymph node metastasis and outcome. Dig Surg 27(2):127–131
doi: 10.1159/000286839 pubmed: 20551657
Sakata J, Shirai Y, Wakai T, Ajioka Y, Akazawa K, Hatakeyama K (2011) Assessment of the nodal status in ampullary carcinoma: the number of positive lymph nodes versus the lymph node ratio. World J Surg 35(9):2118–2124
doi: 10.1007/s00268-011-1175-7 pubmed: 21717240
Palta M, Patel P, Broadwater G et al (2012) Carcinoma of the ampulla of Vater: patterns of failure following resection and benefit of chemoradiotherapy. Ann Surg Oncol 19(5):1535–1540
doi: 10.1245/s10434-011-2117-1 pubmed: 22045467
Robert PE, Leux C, Ouaissi M et al (2014) Predictors of long-term survival following resection for ampullary carcinoma: a large retrospective French multicentric study. Pancreas 43(5):692–697
doi: 10.1097/MPA.0000000000000112 pubmed: 24713843
Colussi O, Voron T, Pozet A et al (2015) Prognostic score for recurrence after Whipple’s pancreaticoduodenectomy for ampullary carcinomas; results of an AGEO retrospective multicenter cohort. Eur J Surg Oncol 41(4):520–526
doi: 10.1016/j.ejso.2015.01.010 pubmed: 25680954
Doepker MP, Thompson ZJ, Centeno BA, Kim RD, Wong J, Hodul PJ (2016) Clinicopathologic and survival analysis of resected ampullary adenocarcinoma. J Surg Oncol 114(2):170–175
doi: 10.1002/jso.24281 pubmed: 27158031 pmcid: 7771532
Kim K, Chie EK, Jang JY et al (2016) Prognostic significance of nodal ratio in patients undergoing adjuvant chemoradiotherapy after curative resection for ampullary cancer. Am J Clin Oncol 39(4):346–349
doi: 10.1097/COC.0000000000000075 pubmed: 24755662
Chen SL, Steele SR, Eberhardt J, Zhu K, Bilchik A, Stojadinovic A (2011) Lymph node ratio as a quality and prognostic indicator in stage III colon cancer. Ann Surg 253(1):82–87
doi: 10.1097/SLA.0b013e3181ffa780 pubmed: 21135690
Wang W, Xu DZ, Li YF et al (2011) Tumor-ratio-metastasis staging system as an alternative to the 7th edition UICC TNM system in gastric cancer after D2 resection–results of a single-institution study of 1343 Chinese patients. Ann Oncol 22(9):2049–2056
doi: 10.1093/annonc/mdq716 pubmed: 21310759
Greenstein AJ, Litle VR, Swanson SJ, Divino CM, Packer S, Wisnivesky JP (2008) Prognostic significance of the number of lymph node metastases in esophageal cancer. J Am Coll Surg 206(2):239–246
doi: 10.1016/j.jamcollsurg.2007.09.003 pubmed: 18222375
Chan JK, Kapp DS, Cheung MK et al (2007) The impact of the absolute number and ratio of positive lymph nodes on survival of endometrioid uterine cancer patients. Br J Cancer 97(5):605–611
doi: 10.1038/sj.bjc.6603898 pubmed: 17667929 pmcid: 2360356
Herr HW (2003) Superiority of ratio based lymph node staging for bladder cancer. J Urol 169(3):943–945
doi: 10.1097/01.ju.0000032474.22093.06 pubmed: 12576818
Partelli S, Crippa S, Capelli P et al (2013) Adequacy of lymph node retrieval for ampullary cancer and its association with improved staging and survival. World J Surg 37(6):1397–1404
doi: 10.1007/s00268-013-1995-8 pubmed: 23546531
Lino-Silva LS, Gómez-Álvarez MA, Salcedo-Hernández RA, Padilla-Rosciano AE, López-Basave HN (2018) Prognostic importance of lymph node ratio after resection of ampullary carcinomas. J Gastrointest Oncol 9(6):1144–1149
doi: 10.21037/jgo.2018.07.04 pubmed: 30603134 pmcid: 6286937
Roland CL, Katz MH, Gonzalez GM et al (2012) A high positive lymph node ratio is associated with distant recurrence after surgical resection of ampullary carcinoma. J Gastrointest Surg 16(11):2056–2063
doi: 10.1007/s11605-012-2015-2 pubmed: 22914983 pmcid: 5131719
Hsu CH, Chen TD, Tsai CY et al (2015) Prognostic value of the metastatic lymph node ratio in patients with resectable carcinoma of ampulla of Vater. Med (Baltim) 94(42):e1859
doi: 10.1097/MD.0000000000001859

Auteurs

Shinichiro Hasegawa (S)

Department of Gastroenterological Surgery, Osaka International Cancer Institute, 3-1-69, Otemae, Chuo-ku, Osaka, 541-8567, Japan.

Hiroshi Wada (H)

Department of Gastroenterological Surgery, Osaka International Cancer Institute, 3-1-69, Otemae, Chuo-ku, Osaka, 541-8567, Japan. wada-hi@oici.jp.

Masahiko Kubo (M)

Department of Gastroenterological Surgery, Osaka International Cancer Institute, 3-1-69, Otemae, Chuo-ku, Osaka, 541-8567, Japan.

Yosuke Mukai (Y)

Department of Gastroenterological Surgery, Osaka International Cancer Institute, 3-1-69, Otemae, Chuo-ku, Osaka, 541-8567, Japan.

Manabu Mikamori (M)

Department of Gastroenterological Surgery, Osaka International Cancer Institute, 3-1-69, Otemae, Chuo-ku, Osaka, 541-8567, Japan.

Hirofumi Akita (H)

Department of Gastroenterological Surgery, Osaka International Cancer Institute, 3-1-69, Otemae, Chuo-ku, Osaka, 541-8567, Japan.

Norihiro Matsuura (N)

Department of Gastroenterological Surgery, Osaka International Cancer Institute, 3-1-69, Otemae, Chuo-ku, Osaka, 541-8567, Japan.

Masatoshi Kitakaze (M)

Department of Gastroenterological Surgery, Osaka International Cancer Institute, 3-1-69, Otemae, Chuo-ku, Osaka, 541-8567, Japan.

Yasunori Masuike (Y)

Department of Gastroenterological Surgery, Osaka International Cancer Institute, 3-1-69, Otemae, Chuo-ku, Osaka, 541-8567, Japan.

Takahito Sugase (T)

Department of Gastroenterological Surgery, Osaka International Cancer Institute, 3-1-69, Otemae, Chuo-ku, Osaka, 541-8567, Japan.

Naoki Shinno (N)

Department of Gastroenterological Surgery, Osaka International Cancer Institute, 3-1-69, Otemae, Chuo-ku, Osaka, 541-8567, Japan.

Takashi Kanemura (T)

Department of Gastroenterological Surgery, Osaka International Cancer Institute, 3-1-69, Otemae, Chuo-ku, Osaka, 541-8567, Japan.

Hisashi Hara (H)

Department of Gastroenterological Surgery, Osaka International Cancer Institute, 3-1-69, Otemae, Chuo-ku, Osaka, 541-8567, Japan.

Toshinori Sueda (T)

Department of Gastroenterological Surgery, Osaka International Cancer Institute, 3-1-69, Otemae, Chuo-ku, Osaka, 541-8567, Japan.

Junichi Nishimura (J)

Department of Gastroenterological Surgery, Osaka International Cancer Institute, 3-1-69, Otemae, Chuo-ku, Osaka, 541-8567, Japan.

Masayoshi Yasui (M)

Department of Gastroenterological Surgery, Osaka International Cancer Institute, 3-1-69, Otemae, Chuo-ku, Osaka, 541-8567, Japan.

Takeshi Omori (T)

Department of Gastroenterological Surgery, Osaka International Cancer Institute, 3-1-69, Otemae, Chuo-ku, Osaka, 541-8567, Japan.

Hiroshi Miyata (H)

Department of Gastroenterological Surgery, Osaka International Cancer Institute, 3-1-69, Otemae, Chuo-ku, Osaka, 541-8567, Japan.

Masayuki Ohue (M)

Department of Gastroenterological Surgery, Osaka International Cancer Institute, 3-1-69, Otemae, Chuo-ku, Osaka, 541-8567, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH